Kexing Biopharm’s GB18 project received clearance of IND application from NMPA and FDA
On May 26th, Kexing Biopharm (688136.SH) announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its independently developed innovative...